ACCESS Newswire

Photonis

18.1.2024 15:02:37 CET | ACCESS Newswire | Press release

Share
New Cutting-Edge 25 mm Image Intensifier to be Unveiled at SPIE Photonics West 2024

SAN FRANCISCO, CA / ACCESSWIRE / January 18, 2024 / Exosens is proud to announce the expansion of Photonis' Ultimate Detection Scientific Imaging product portfolio with the introduction of the 25 mm Image Intensifier solution. This latest technology will be showcased at SPIE Photonics West from January 30 to February 1 at the Exosens booth #3273. This event will provide an excellent opportunity for attendees to explore Photonis' cutting-edge 25 mm Image Intensifier model and other state-of-the-art technologies.

To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
Photonics West

Based on Photonis market-leading Hi-CE MCP technology, and available with advanced Hi-QE photocathodes, Photonis Image Intensifiers are widely recognized for their high quality and top-tier specifications. Available configurations include Single MCP, Dual MCP, and Proximity Focused Diode models all offering superb signal-to-noise ratio, spatial resolution, and gating characteristics.

Driven by a demand for increased active detection area in life science and scientific imaging applications, Photonis now offers ultra-high speed and scientific camera manufacturers their upgraded 25 mm Image Intensifier technology next to their well-established 18 mm and 40 mm range.

"For decades, Photonis has been a leading technology brand for scientific and ultra-highspeed camera manufacturers worldwide, providing them the highest quality intensifier solutions with unprecedented performance and support. With the introduction of the new 25 mm variant now complementing the Scientific Image Intensifier lineup, camera manufacturers can provide scientists and researchers with high-end intensified imaging solutions for every application," said Ulrich Laupper - President and Executive GM of Exosens Ultimate Detection Business.

ABOUT PHOTONIS:

Photonis is a leading product brand of Exosens, a high-tech company with more than 85 years of experience in the innovation, development, manufacture, and sale of high-end electro-optical technologies used in the detection and amplification of ions, electrons, and photons. Photonis offers its customers photo-detection and low-light conditions imaging solutions for extremely demanding environments such as Defense & Security, Nuclear Safety, Life Science, and Industrial & Non-Destructive testing. Photonis is internationally recognized as a leading brand and a major innovator in its fields with production and R&D sites in Europe and North America.

For more information:

exosens.com
science@exosens.com

FORWARD-LOOKING STATEMENT:

Certain information included in this press release are not historical facts but are forward-looking statements. These forward-looking statements are based on current beliefs, expectations, and assumptions, including, without limitation, assumptions regarding present and future business strategies and the environment in which Exosens operates, and involve known and unknown risks, uncertainties, and other factors, which may cause actual results, performance or achievements to be materially different from the forward-looking statements included in this press release.

Contact Information:

Sikke Lautenbach
Sales & Business Development Manager
s.lautenbach@exosens.com

SOURCE: Photonis Netherlands BV

To view this piece of content from stats.newswire.com, please give your consent at the top of this page.

View the original press release on newswire.com.

To view this piece of content from www.accesswire.com, please give your consent at the top of this page.

About ACCESS Newswire

DK

Subscribe to releases from ACCESS Newswire

Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from ACCESS Newswire

OBI Pharma Signs Collaboration and License Agreement with Novartis16.11.2026 09:10:00 CET | Press release

TAIPEI, TW / ACCESS Newswire / November 16, 2026 / OBI Pharma, Inc. (4174.TWO) ("OBI") announced that it has entered into a Collaboration and License agreement with Novartis Pharma AG ("Novartis") to develop next generation Antibody-Drug-Conjugates (ADCs) with novel payloads, using OBI's suite of platform technologies. Under the terms of the agreement, Novartis will receive worldwide rights to OBI's related patents and know-how using its ADC platform technologies on an exclusive basis for selected, undisclosed Novartis payload classes. In parallel, under the collaboration OBI will evaluate novellinker approaches with the Novartis payloads. Novartis will further have the option to expand the agreement to include additional novel payload classes. This agreement marks an important milestone for OBI and underscores the value of its differentiated ADC technology platform. The agreement recognizes the potential of OBI's proprietary technologies, including GlycOBI®, EndoSymeOBI®, HYPrOBI®, an

Digi Power X Reports Q3 2026 Revenue Up 85% and AI Revenue Up Over 400% Compared to Q213.11.2026 13:30:00 CET | Press release

MIAMI, FL / ACCESS Newswire / November 13, 2026 / Digi Power X Inc. (Nasdaq:DGXX)(Cboe Canada:DGX) ("Digi Power X" or the "Company"), an AI data center infrastructure operator, today reported its financial and operating results for the third quarter ended September 30, 2026 (all amounts in U.S. dollars, unless otherwise indicated). The Company's quarterly report on Form 10-Q, which includes unaudited consolidated financial statements and management's discussion and analysis ("MD&A") for the quarter ended September 30, 2026, is being filed and made accessible under the Company's continuous disclosure profile on SEDAR+ at www.sedarplus.ca and will also be available on EDGAR at www.sec.gov/edgar. Third Quarter 2026 Highlights All amounts in U.S. dollars (millions) Revenue of $12.25 million, up 85% from the previously completed fiscal quarter and an increase of 50% compared to the quarter ended September 30, 2025; $119.6 million in cash, cash equivalents and digital currencies, $103.0 mill

Fermi Announces New Agreements with Investment-Grade Hyperscaler and Third Quarter 2026 Financial Results12.11.2026 13:00:00 CET | Press release

DALLAS, TX / ACCESS Newswire / November 12, 2026 / Fermi Inc. (NASDAQ:FRMI)(LSE:FRMI), operating as Fermi America™ ("Fermi" or the "Company"), today announced its third quarter 2026 financial results and multiple new agreements with an investment-grade hyperscaler to advance 600 megawatts ("MW") of power capacity at Project Matador. A conference call is scheduled for 9 a.m. Eastern Time / 2 p.m. British Time today, November 12, 2026. Accompanying slides and prepared remarks can be found at https://investor.fermiamerica.com. Participation details are included in this release. "Hyperscalers want sites that are ready with permitted power, and Fermi's Project Matador is one of few that can meet that demand today," said Lee McIntire, Fermi Chief Executive Officer. "Our headstart in speed to power is a key reason an investment-grade hyperscaler has signed up for 600 megawatts and committed more than $200 million up front to accelerate construction at Project Matador with an additional $90 mi

Nexteer Announces First Share Repurchase Programme of Up to US$60 Million12.11.2026 01:40:00 CET | Press release

HONG KONG, HK / ACCESS Newswire / November 11, 2026 / Nexteer Automotive today announced that its Board of Directors has approved, the Company's first share repurchase programme of up to US$60 million, equivalent to approximately HK$471 million. The programme reflects the Board's confidence in Nexteer's business and long-term prospects. The Group's strong liquidity position supports returning capital to shareholders while continuing to invest in the business and its future development. Disciplined Capital Allocation The programme complements Nexteer's dividend distributions and represents a further step in returning capital to shareholders. It follows the dividend paid out in July 2026 of approximately US$46 million, representing 45% of the Company's net income attributable to shareholders for the year ending December 31, 2025 -and the highest dividend payout ratio in the Company's history. Nexteer remains committed to disciplined capital allocation, balancing investment in the busines

GoodData.AI Launches the Agentic Serving Plane, a New Category of Enterprise Data Infrastructure for AI Agents10.11.2026 15:30:00 CET | Press release

SAN FRANCISCO, CA / ACCESS Newswire / November 10, 2026 / GoodData.AI, the open agentic analytics platform, today launched the Agentic Serving Plane, a governed execution layer designed for the high-concurrency, context-rich data workloads created by AI agents. The Agentic Serving Plane sits between enterprise data platforms and the applications, analytics experiences and agents that consume them. It provides workload serving, business semantics, contextual grounding, access control, and AI execution services through a common governed layer. The current enterprise data infrastructure was designed primarily for humans: occasional queries, predictable workloads, and access by known users. AI agents operate differently. A single business task can generate tens or hundreds of short-lived data operations as an agent investigates, reasons, and decides what to ask next. When many agents operate simultaneously, intermittent human querying becomes continuous, high-concurrency agentic demand. Ag

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye